Do analysts rate ALEC or GNTA?

Alector presently has a consensus target price of $3.63, indicating a potential upside of 98.09%. Given Alector's stronger consensus rating and higher possible upside, equities research analysts plainly believe Alector is more favorable than Genenta Science. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alector 2 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.13 Genenta Science 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation & earnings, ALEC or GNTA?

Genenta Science has lower revenue, but higher earnings than Alector. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alector $21.05M 9.65 -$142.93M -$1.19 N/A Genenta Science N/A N/A -$7.39M N/A N/A

Do analysts prefer PRQR or GNTA?

ProQR Therapeutics presently has a consensus target price of $7.25, suggesting a potential upside of 283.60%. Given ProQR Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe ProQR Therapeutics is more favorable than Genenta Science. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ProQR Therapeutics 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.63 Genenta Science 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, PRQR or GNTA?

Genenta Science has lower revenue, but higher earnings than ProQR Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ProQR Therapeutics $17.99M 11.07 -$47.73M -$0.50 N/A Genenta Science N/A N/A -$7.39M N/A N/A

Do analysts recommend ADAG or GNTA?

Adagene currently has a consensus target price of $8.00, suggesting a potential upside of 101.01%. Given Adagene's stronger consensus rating and higher possible upside, analysts clearly believe Adagene is more favorable than Genenta Science. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adagene 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.00 Genenta Science 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, ADAG or GNTA?

Genenta Science has lower revenue, but higher earnings than Adagene. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adagene $7.67M 24.59 -$17.61M N/A N/A Genenta Science N/A N/A -$7.39M N/A N/A

Is ADAG or GNTA more profitable?

Company Net Margins Return on Equity Return on Assets Adagene N/A N/A N/A Genenta Science N/A N/A N/A

Do analysts prefer GNTA or DTIL?

Precision BioSciences has a consensus price target of $32.25, suggesting a potential upside of 364.03%. Given Precision BioSciences' stronger consensus rating and higher probable upside, analysts plainly believe Precision BioSciences is more favorable than Genenta Science. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genenta Science 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Precision BioSciences 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60

Which has better valuation and earnings, GNTA or DTIL?

Genenta Science has higher earnings, but lower revenue than Precision BioSciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Genenta Science N/A N/A -$7.39M N/A N/A Precision BioSciences $34.26M 5.23 -$45.72M -$3.67 N/A

Do analysts prefer DERM or GNTA?

Journey Medical presently has a consensus price target of $13.00, suggesting a potential upside of 94.03%. Given Journey Medical's stronger consensus rating and higher probable upside, equities research analysts plainly believe Journey Medical is more favorable than Genenta Science. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Journey Medical 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Genenta Science 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, DERM or GNTA?

Genenta Science has lower revenue, but higher earnings than Journey Medical. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Journey Medical $61.86M 2.98 -$11.43M -$0.37 N/A Genenta Science N/A N/A -$7.39M N/A N/A

Genenta Science (GNTA) Competitors

$1.84 -0.08 (-4.17%)

Closing price 04:00 PM Eastern

Extended Trading

$1.84 +0.00 (+0.22%)

As of 07:34 PM Eastern

Compare

GNTA vs. ALEC, PRQR, ADAG, DTIL, and DERM

Should you buy Genenta Science stock or one of its competitors? MarketBeat compares Genenta Science with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Genenta Science include Alector (ALEC), ProQR Therapeutics (PRQR), Adagene (ADAG), Precision BioSciences (DTIL), and Journey Medical (DERM). These companies are all part of the "pharmaceutical products" industry.

How does Genenta Science compare to Alector?

Alector (NASDAQ:ALEC) and Genenta Science (NASDAQ:GNTA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

Genenta Science has a net margin of 0.00% compared to Alector's net margin of -680.83%. Genenta Science's return on equity of 0.00% beat Alector's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alector	-680.83%	-295.17%	-40.95%
Genenta Science	N/A	N/A	N/A

85.8% of Alector shares are owned by institutional investors. Comparatively, 15.1% of Genenta Science shares are owned by institutional investors. 8.3% of Alector shares are owned by company insiders. Comparatively, 29.0% of Genenta Science shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Alector has a beta of 0.61, meaning that its share price is 39% less volatile than the broader market. Comparatively, Genenta Science has a beta of 0.9, meaning that its share price is 10% less volatile than the broader market.

Genenta Science has lower revenue, but higher earnings than Alector.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alector	$21.05M	9.65	-$142.93M	-$1.19	N/A
Genenta Science	N/A	N/A	-$7.39M	N/A	N/A

In the previous week, Alector had 3 more articles in the media than Genenta Science. MarketBeat recorded 3 mentions for Alector and 0 mentions for Genenta Science. Alector's average media sentiment score of 1.02 beat Genenta Science's score of 0.00 indicating that Alector is being referred to more favorably in the media.

Company	Overall Sentiment
Alector	Positive
Genenta Science	Neutral

Alector presently has a consensus target price of $3.63, indicating a potential upside of 98.09%. Given Alector's stronger consensus rating and higher possible upside, equities research analysts plainly believe Alector is more favorable than Genenta Science.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alector	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13
Genenta Science	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Alector beats Genenta Science on 7 of the 13 factors compared between the two stocks.

How does Genenta Science compare to ProQR Therapeutics?

ProQR Therapeutics (NASDAQ:PRQR) and Genenta Science (NASDAQ:GNTA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

Genenta Science has a net margin of 0.00% compared to ProQR Therapeutics' net margin of -331.33%. Genenta Science's return on equity of 0.00% beat ProQR Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProQR Therapeutics	-331.33%	-84.87%	-37.78%
Genenta Science	N/A	N/A	N/A

32.7% of ProQR Therapeutics shares are owned by institutional investors. Comparatively, 15.1% of Genenta Science shares are owned by institutional investors. 8.4% of ProQR Therapeutics shares are owned by company insiders. Comparatively, 29.0% of Genenta Science shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

ProQR Therapeutics has a beta of 0.07, indicating that its stock price is 93% less volatile than the broader market. Comparatively, Genenta Science has a beta of 0.9, indicating that its stock price is 10% less volatile than the broader market.

Genenta Science has lower revenue, but higher earnings than ProQR Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProQR Therapeutics	$17.99M	11.07	-$47.73M	-$0.50	N/A
Genenta Science	N/A	N/A	-$7.39M	N/A	N/A

In the previous week, ProQR Therapeutics' average media sentiment score of 0.00 equaled Genenta Science'saverage media sentiment score.

Company	Overall Sentiment
ProQR Therapeutics	Neutral
Genenta Science	Neutral

ProQR Therapeutics presently has a consensus target price of $7.25, suggesting a potential upside of 283.60%. Given ProQR Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe ProQR Therapeutics is more favorable than Genenta Science.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProQR Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Genenta Science	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Genenta Science beats ProQR Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Genenta Science compare to Adagene?

Adagene (NASDAQ:ADAG) and Genenta Science (NASDAQ:GNTA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, media sentiment, risk, profitability, dividends and analyst recommendations.

Adagene has a beta of 0.59, indicating that its share price is 41% less volatile than the broader market. Comparatively, Genenta Science has a beta of 0.9, indicating that its share price is 10% less volatile than the broader market.

Adagene currently has a consensus target price of $8.00, suggesting a potential upside of 101.01%. Given Adagene's stronger consensus rating and higher possible upside, analysts clearly believe Adagene is more favorable than Genenta Science.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adagene	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.00
Genenta Science	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

9.5% of Adagene shares are owned by institutional investors. Comparatively, 15.1% of Genenta Science shares are owned by institutional investors. 21.2% of Adagene shares are owned by insiders. Comparatively, 29.0% of Genenta Science shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Company	Net Margins	Return on Equity	Return on Assets
Adagene	N/A	N/A	N/A
Genenta Science	N/A	N/A	N/A

In the previous week, Adagene had 1 more articles in the media than Genenta Science. MarketBeat recorded 1 mentions for Adagene and 0 mentions for Genenta Science. Adagene's average media sentiment score of 0.36 beat Genenta Science's score of 0.00 indicating that Adagene is being referred to more favorably in the media.

Company	Overall Sentiment
Adagene	Neutral
Genenta Science	Neutral

Genenta Science has lower revenue, but higher earnings than Adagene.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adagene	$7.67M	24.59	-$17.61M	N/A	N/A
Genenta Science	N/A	N/A	-$7.39M	N/A	N/A

Summary

Adagene beats Genenta Science on 7 of the 11 factors compared between the two stocks.

How does Genenta Science compare to Precision BioSciences?

Genenta Science (NASDAQ:GNTA) and Precision BioSciences (NASDAQ:DTIL) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends, media sentiment and earnings.

In the previous week, Precision BioSciences' average media sentiment score of 1.34 beat Genenta Science's score of 0.00 indicating that Precision BioSciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Genenta Science	Neutral
Precision BioSciences	Positive

Precision BioSciences has a consensus price target of $32.25, suggesting a potential upside of 364.03%. Given Precision BioSciences' stronger consensus rating and higher probable upside, analysts plainly believe Precision BioSciences is more favorable than Genenta Science.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genenta Science	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Precision BioSciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Genenta Science has higher earnings, but lower revenue than Precision BioSciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genenta Science	N/A	N/A	-$7.39M	N/A	N/A
Precision BioSciences	$34.26M	5.23	-$45.72M	-$3.67	N/A

Genenta Science has a net margin of 0.00% compared to Precision BioSciences' net margin of -96.73%. Genenta Science's return on equity of 0.00% beat Precision BioSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genenta Science	N/A	N/A	N/A
Precision BioSciences	-96.73%	-85.37%	-37.34%

Genenta Science has a beta of 0.9, suggesting that its stock price is 10% less volatile than the broader market. Comparatively, Precision BioSciences has a beta of 1.3, suggesting that its stock price is 30% more volatile than the broader market.

15.1% of Genenta Science shares are owned by institutional investors. Comparatively, 38.0% of Precision BioSciences shares are owned by institutional investors. 29.0% of Genenta Science shares are owned by insiders. Comparatively, 2.7% of Precision BioSciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Precision BioSciences beats Genenta Science on 7 of the 12 factors compared between the two stocks.

How does Genenta Science compare to Journey Medical?

Journey Medical (NASDAQ:DERM) and Genenta Science (NASDAQ:GNTA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, profitability, institutional ownership, dividends, media sentiment and valuation.

7.3% of Journey Medical shares are owned by institutional investors. Comparatively, 15.1% of Genenta Science shares are owned by institutional investors. 14.5% of Journey Medical shares are owned by company insiders. Comparatively, 29.0% of Genenta Science shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Journey Medical's average media sentiment score of 0.00 equaled Genenta Science'saverage media sentiment score.

Company	Overall Sentiment
Journey Medical	Neutral
Genenta Science	Neutral

Journey Medical presently has a consensus price target of $13.00, suggesting a potential upside of 94.03%. Given Journey Medical's stronger consensus rating and higher probable upside, equities research analysts plainly believe Journey Medical is more favorable than Genenta Science.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Journey Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Genenta Science	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Journey Medical has a beta of 1.09, suggesting that its share price is 9% more volatile than the broader market. Comparatively, Genenta Science has a beta of 0.9, suggesting that its share price is 10% less volatile than the broader market.

Genenta Science has lower revenue, but higher earnings than Journey Medical.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Journey Medical	$61.86M	2.98	-$11.43M	-$0.37	N/A
Genenta Science	N/A	N/A	-$7.39M	N/A	N/A

Genenta Science has a net margin of 0.00% compared to Journey Medical's net margin of -14.82%. Genenta Science's return on equity of 0.00% beat Journey Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Journey Medical	-14.82%	-35.57%	-10.88%
Genenta Science	N/A	N/A	N/A

Summary

Genenta Science beats Journey Medical on 6 of the 11 factors compared between the two stocks.

Get Genenta Science News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GNTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GNTA vs. The Competition

Export

Metric	Genenta Science	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$45.29M	$3.45B	$6.45B	$12.39B
Dividend Yield	N/A	2.30%	2.69%	5.83%
P/E Ratio	N/A	19.75	24.92	23.98
Price / Sales	N/A	330.11	529.01	109.54
Price / Cash	N/A	128.56	44.82	54.51
Price / Book	1.43	8.29	10.79	6.50
Net Income	-$7.39M	$23.85M	$3.56B	$336.88M
7 Day Performance	-1.60%	5.21%	1.67%	-0.22%
1 Month Performance	217.24%	2.19%	0.43%	0.77%
1 Year Performance	-39.87%	60.99%	32.84%	31.57%

Genenta Science Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GNTA Genenta Science	0.2381 of 5 stars	$1.84 -4.2%	N/A	-37.5%	$45.29M	N/A	N/A	7	Gap Down
ALEC Alector	3.0805 of 5 stars	$1.58 +2.3%	$3.63 +130.2%	+21.1%	$174.86M	$18.42M	N/A	270	Positive News
PRQR ProQR Therapeutics	2.1653 of 5 stars	$1.66 +8.9%	$7.25 +338.1%	-2.6%	$174.37M	$13.42M	N/A	180
ADAG Adagene	2.5132 of 5 stars	$3.68 +5.0%	$8.00 +117.2%	+102.1%	$173.31M	$7.67M	N/A	260	News Coverage Gap Down
DTIL Precision BioSciences	2.6719 of 5 stars	$6.71 +6.3%	$32.25 +380.6%	+47.8%	$173.13M	$45.07M	N/A	200	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GNTA) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Genenta Science (GNTA) Competitors

GNTA vs. ALEC, PRQR, ADAG, DTIL, and DERM

How does Genenta Science compare to Alector?

Summary

How does Genenta Science compare to ProQR Therapeutics?

Summary

How does Genenta Science compare to Adagene?

Summary

How does Genenta Science compare to Precision BioSciences?

Summary

How does Genenta Science compare to Journey Medical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GNTA vs. The Competition

Genenta Science Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Genenta Science (GNTA) Competitors

GNTA vs. ALEC, PRQR, ADAG, DTIL, and DERM

How does Genenta Science compare to Alector?

Is ALEC or GNTA more profitable?

Do institutionals & insiders believe in ALEC or GNTA?

Which has more volatility & risk, ALEC or GNTA?

Which has stronger valuation & earnings, ALEC or GNTA?

Does the media prefer ALEC or GNTA?

Do analysts rate ALEC or GNTA?

Summary

How does Genenta Science compare to ProQR Therapeutics?

Is PRQR or GNTA more profitable?

Do insiders and institutionals have more ownership in PRQR or GNTA?

Which has more volatility & risk, PRQR or GNTA?

Which has better valuation and earnings, PRQR or GNTA?

Does the media prefer PRQR or GNTA?

Do analysts prefer PRQR or GNTA?

Summary

How does Genenta Science compare to Adagene?

Which has more volatility and risk, ADAG or GNTA?

Do analysts recommend ADAG or GNTA?

Do institutionals & insiders have more ownership in ADAG or GNTA?

Is ADAG or GNTA more profitable?

Does the media refer more to ADAG or GNTA?

Which has better earnings & valuation, ADAG or GNTA?

Summary

How does Genenta Science compare to Precision BioSciences?

Does the media prefer GNTA or DTIL?

Do analysts prefer GNTA or DTIL?

Which has better valuation and earnings, GNTA or DTIL?

Is GNTA or DTIL more profitable?

Which has more volatility and risk, GNTA or DTIL?

Do institutionals & insiders hold more shares of GNTA or DTIL?

Summary

How does Genenta Science compare to Journey Medical?

Do insiders and institutionals hold more shares of DERM or GNTA?

Does the media favor DERM or GNTA?

Do analysts prefer DERM or GNTA?

Which has more risk and volatility, DERM or GNTA?

Which has preferable earnings and valuation, DERM or GNTA?

Is DERM or GNTA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GNTA vs. The Competition

Genenta Science Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools